Simple and Effective Screening tool for supporting early detection of brain cancer

简单有效的筛查工具，支持早期发现脑癌

• 批准号: 10027624
• 金额: $ 56.22万
• 依托单位: FLUORETIQ LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10027624
• 关键词: Simple; Effective; Screening; tool; supporting

Brain tumours reduce the life expectancy for an average patient by 20 years. In the UK in 2013: 38 % of brain tumour patients visited their GP 5 times or more, typically over 15 weeks, before diagnosis because symptoms such as headache are non-specific. Although headaches are strongly associated with brain cancer, the chance of a patient with headache having brain cancer is very low, meaning that many worried well patients undergo negative MRI/CT scans to exclude diagnosis. Less than 1% of patients who have a CT/MRI scan actually require intervention/neurorehabilitation. In the UK, a patient develops a brain tumour every hour \[1\], it is therefore important to develop tools to enable earlier detection of brain cancer and ensure the right patients get access to the costly CT/MRI infrastructure.Our goal is to develop a simple blood test for quantifying serum levels of GFAP at the GP-level to aid decision-making and early diagnosis. This would revolutionise care by speeding up diagnosis, reducing costs and anxiety of unnecessary scans and reducing the number of patients presenting with inoperable large brain tumours.

脑肿瘤使平均患者的预期寿命减少20年。2013年在英国：38%的脑肿瘤患者在诊断前拜访了他们的GP 5次或更多次，通常超过15周，因为头痛等症状是非特异性的。虽然头痛与脑癌密切相关，但头痛患者患脑癌的几率非常低，这意味着许多担心的患者接受阴性MRI/CT扫描以排除诊断。只有不到1%的接受CT/MRI扫描的患者实际上需要干预/神经康复。在英国，每小时就有一名患者患上脑肿瘤，因此，开发工具以早期发现脑癌并确保合适的患者能够获得昂贵的CT/MRI基础设施是非常重要的。我们的目标是开发一种简单的血液测试，用于在GP水平上定量血清GFAP水平，以帮助决策和早期诊断。这将通过加快诊断速度、降低不必要扫描的成本和焦虑以及减少患有无法手术的大型脑肿瘤的患者数量来彻底改变护理。